BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 1705008)

  • 1. Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins.
    McWhirter JR; Wang JY
    Mol Cell Biol; 1991 Mar; 11(3):1553-65. PubMed ID: 1705008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias.
    McWhirter JR; Wang JY
    EMBO J; 1993 Apr; 12(4):1533-46. PubMed ID: 8467803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor.
    Pendergast AM; Muller AJ; Havlik MH; Clark R; McCormick F; Witte ON
    Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5927-31. PubMed ID: 1712111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein.
    McWhirter JR; Wang JY
    Oncogene; 1997 Oct; 15(14):1625-34. PubMed ID: 9349495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.
    Pendergast AM; Quilliam LA; Cripe LD; Bassing CH; Dai Z; Li N; Batzer A; Rabun KM; Der CJ; Schlessinger J
    Cell; 1993 Oct; 75(1):175-85. PubMed ID: 8402896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A limited set of SH2 domains binds BCR through a high-affinity phosphotyrosine-independent interaction.
    Muller AJ; Pendergast AM; Havlik MH; Puil L; Pawson T; Witte ON
    Mol Cell Biol; 1992 Nov; 12(11):5087-93. PubMed ID: 1383690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine phosphorylation of P160 BCR by P210 BCR-ABL.
    Lu D; Liu J; Campbell M; Guo JQ; Heisterkamp N; Groffen J; Canaani E; Arlinghaus R
    Blood; 1993 Aug; 82(4):1257-63. PubMed ID: 8353288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.
    McWhirter JR; Galasso DL; Wang JY
    Mol Cell Biol; 1993 Dec; 13(12):7587-95. PubMed ID: 8246975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein.
    Liu J; Wu Y; Arlinghaus RB
    Cancer Res; 1996 Nov; 56(22):5120-4. PubMed ID: 8912843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
    Sattler M; Salgia R; Okuda K; Uemura N; Durstin MA; Pisick E; Xu G; Li JL; Prasad KV; Griffin JD
    Oncogene; 1996 Feb; 12(4):839-46. PubMed ID: 8632906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a protein that binds to the SH3 region of Abl and is similar to Bcr and GAP-rho.
    Cicchetti P; Mayer BJ; Thiel G; Baltimore D
    Science; 1992 Aug; 257(5071):803-6. PubMed ID: 1379745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner.
    Pendergast AM; Muller AJ; Havlik MH; Maru Y; Witte ON
    Cell; 1991 Jul; 66(1):161-71. PubMed ID: 1712671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
    Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K
    Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An activating mutation in the ATP binding site of the ABL kinase domain.
    Allen PB; Wiedemann LM
    J Biol Chem; 1996 Aug; 271(32):19585-91. PubMed ID: 8702653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
    He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
    Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.
    Carlesso N; Frank DA; Griffin JD
    J Exp Med; 1996 Mar; 183(3):811-20. PubMed ID: 8642285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.
    Muller AJ; Young JC; Pendergast AM; Pondel M; Landau NR; Littman DR; Witte ON
    Mol Cell Biol; 1991 Apr; 11(4):1785-92. PubMed ID: 2005881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
    Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R
    J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway.
    Bassermann F; Jahn T; Miething C; Seipel P; Bai RY; Coutinho S; Tybulewicz VL; Peschel C; Duyster J
    J Biol Chem; 2002 Apr; 277(14):12437-45. PubMed ID: 11790798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.
    Arlinghaus RB
    Oncogene; 2002 Dec; 21(56):8560-7. PubMed ID: 12476302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.